Urothelial Carcinoma With a Novel MET Exon 14 Skipping Alteration

This case broadens the spectrum of MET exon 14 skipping events in UC by documenting a novel intronic c.2942-22_2942-19delCTTT alteration in plasmacytoid carcinoma. It underscores the importance of routine genomic profiling in advanced and histologically rare UC to uncover targetable alterations and supports consideration of MET-directed therapies or enrollment in tumor-agnostic trials for selected patients, while highlighting the need for further functional and clinical validation.